Table I.
Patient characteristics (n=129).
| Characteristic | Value |
|---|---|
| Age, years | |
| Median | 57 |
| Range | 24–83 |
| Gender, n | |
| Female | 48 |
| Male | 81 |
| Performance status, n | |
| 0 | 33 |
| 1 | 80 |
| Unknown | 16 |
| LDH (at baseline; U/l), n | |
| ≤220 | 42 |
| >220 | 83 |
| Unknown | 4 |
| AJCC M stage, n | |
| M1a | 9 |
| M1b | 11 |
| M1c | 109 |
| Ipilimumab - line of treatment, n | |
| Second line | 80 |
| Third line | 36 |
| Fourth line | 7 |
| ≥Fifth line | 6 |
| Treatments prior to ipilimumab, n | |
| Chemotherapy | 105 |
| Targeted agent/BRAF inhibitor | 29 |
| Pembrolizumab (anti-PD1 antibody) | 7 |
| High dose interleukin-2/other immunotherapy | 10 |
| Trial (experimental agent) | 28 |
| BRAF mutation statusa, n | |
| Positive | 33 |
| Negative | 68 |
| NRAS mutation statusa, n | |
| Positive | 13 |
| Negative | 10 |
| KIT mutation statusa, n | |
| Positive | 0 |
| Negative | 5 |
a
Where tested. LDH, lactate dehydrogenase; AJCC, American Joint Committee on Cancer staging system; PD1, programmed cell death 1; NRAS, neuroblastoma RAS oncogene.